Low leucocyte myeloperoxidase activity in patients with multiple sclerosis
- 1Department of Neurology, Academisch Ziekenhuis Groningen, Groningen, Netherlands
- 2Laboratory of Perinatal Biochemistry, D.O. Ott Research Institute of Obstetrics and Gynecology, Russian Academy of Medical Sciences, St Petersburg, Russia
- Correspondence to: Professor J De Keyser, Department of Neurology, Academisch Ziekenhuis Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands; j.h.a.de.keyser{at}neuro.azg.nl
Abstract
The gene for myeloperoxidase (MPO) has been implicated in multiple sclerosis (MS). By measuring H2O2 dependent oxidation of 3,3′5,5′-tetramethylbenzidine with spectrophotometry the authors investigated MPO activity in peripheral blood leucocytes from 42 patients with MS (12 with secondary progressive MS, 17 with primary progressive MS, and 13 with relapsing remitting benign MS) and 32 healthy controls. Leucocyte MPO activity was significantly lower in patients with benign MS (mean (SEM) 0.086 (0.029) U/mg protein; p<0.01), secondary progressive MS (0.038 (0.009) U/mg protein; p<0.001), and primary progressive MS (0.057 (0.016) U/mg protein; p<0.001) compared with healthy controls (0.322 (0.053) U/mg protein). These data suggest that low MPO, which may be genetically determined, plays a part in MS pathogenesis.
- MPO, myeloperoxidase
- MS, multiple sclerosis
- EAE, experimental allergic encephalitis
- BMS, benign multiple sclerosis
- SPMS, secondary progressive multiple sclerosis
- PPMS, primary progressive multiple sclerosis
Footnotes
-
Funding: this work was supported by Multiple Sclerosis Internationaal (MSI), Amsterdam.
-
Competing interests: none declared.
